LeXHema Panel

A: Fusion genes are pivotal molecular markers in the diagnosis and treatment of hematologic malignancies. While DNA-based detection is a standard approach, relying solely on DNA poses significant challenges. Many fusions occur within large, highly repetitive intronic regions, making them costly to cover and difficult to map accurately. Furthermore, DNA analysis cannot confirm whether a genomic rearrangement results in a functional, transcribed product.

By integrating DNA and RNA workflows, the LeXHema system provides a “Dual Safeguard“ for your research:

• DNA Workflow: Identifies the structural genomic breakpoints.
• RNA Workflow: Focuses on the transcript level to precisely identify active fusion events and their partner genes, confirming the functional impact and aberrant transcription. This synergistic approach significantly increases both the analytical comprehensiveness and the clinical accuracy of your results.

A: While Total RNA-Seq is a common method, it often suffers from high complexity and cost due to the necessity of rRNA depletion and individual sample reactions. More importantly, Total RNA-Seq often lacks the sensitivity required to detect low-frequency fusion events, especially in samples with low expression levels.

The LeXHema Panel offers a superior alternative:

• Targeted Sensitivity: Our capture-based enrichment significantly boosts the signal-to-noise ratio for rare transcripts.
• Integrated Intronic Coverage: The DNA portion of the LeXHema Panel already includes critical intronic regions for key genes.
• Economic Flexibility: Users can selectively add custom intronic regions based on their specific research goals and budget, eliminating the need for a separate, costly RNA-only panel and streamlining the entire laboratory process.

A: Yes. Although LeXHema Panel is a comprehensive solution covering a broad spectrum of variants associated with hematologic malignancies, we recognize that different clinical and research scenarios require specialized focus. To support your specific needs, we offer two primary levels of customization:

• Modular Sub-Panels: The master panel can be strategically split into targeted sub-panels (e.g., focused exclusively on AML, Lymphoblastic Leukemia, T-cell Lymphoma, or B-cell Lymphoma).
• Bespoke Gene Expansion: Additional target genes or specific regions of interest can be incorporated into the existing architecture, allowing you to create a truly personalized diagnostic or research solution.

For technical consultations or to request a customized panel design, please contact our team at support@lexigenbio.com